Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

NCT05420727 | Completed Phase 1

• 1 other identifier: Theranostics STS
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.

Conditions

Soft Tissue Sarcoma

Outcome Measures

Primary Outcomes (1)

• imaging result obtained by Ga-68-PSMA-11 PET/CT

  four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line

Secondary Outcomes (2)

• SUVmax and radiological changes using PSMA - PET/CT

  four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line.

• Tumor evaluation using contrast enhanced computed tomography (ceCT)

  four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line.

Study Arms (1)

Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1

EXPERIMENTAL

Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.

Drug: Ga-68-PSMA-11 PET/CT; Drug: Lu-177-ITG-PSMA-1

Interventions

Ga-68-PSMA-11 PET/CT DRUG

Ga-68-PSMA-11 PET/CT imaging

Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1

Lu-177-ITG-PSMA-1 DRUG

Lu-177-ITG-PSMA-1 treatment

Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female or male ≥ 18 years old at the time of informed consent
• Patients with proven Soft Tissue Sarcoma
• Patients need to pass the sarcoma tumor board and the molecular tumor board at CHUV and no approved therapeutic alternative is available
• Progression of the disease by RECIST v1.1 after standard therapies according to the treat-ing oncologists
• Informed Consent as documented by signed informed consent form

You may not qualify if:

• Patients under active anti-sarcoma treatment other than the study product (Lu-177-ITG-PSMA-1)
• Female participants who are pregnant or breast feeding
• Female participants with intention to become pregnant during the course of the study
• Lack of safe contraception, defined as: Female participants of childbearing potential, not us-ing and not willing to continue using a medically reliable method of contraception for the en-tire study duration until 6 months after last Lu-177-ITG-PSMA-1 treatment, such as oral, in-jectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Male patients of reproductive potential, not using and not willing to use a medically reliable method of contraception for the entire study duration until 6 months after last Lu-177-ITG-PSMA-1 treatment, such as barrier method or sexual abstinence or who are not using any other method considered sufficiently reliable by the investigator in individual cases. The par-ticipant must inform their female partners about the participation in this trial and they must use additional effective contraception (e.g., hormonal) during the trial until 6 months after the last Lu-177-ITG-PSMA-1 treatment.
• Previous enrolment into the current study
• History of any disease or relevant physical condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
• Insufficient knowledge of project language, inability to give consent or to follow procedures, incapacity to follow radiation safety procedures, required by the study
• Enrolment of the investigator, his/her family members, employees and other dependent per-sons
• The patient makes use of his/her "right not to know" and refuses to be informed about inci-dental findings
• Absence of PSMA accumulation in at least 50% of tumours on Ga-68-PSMA-11 PET/CT
• Grade IV renal impairment and above (calculated GFR \< 30 mL/min/1.73 m2)
• Blood count disturbance:
• Platelets \< 75,000/µL. Leukocytes \< 2,500/µL Haemoglobin \< 80 g/L. • Disturbance of liver function with: Total bilirubin \> 2 times the upper limit of the norm ASAT/ALAT \> 3 times the upper limit without the presence of liver metastases ASAT/ALAT \> 5 times the upper limit in the presence of liver metastases
• Hypersensitivity to any of the ingredients of the injectable product

Sponsors & Collaborators

• John O. Prior: lead

Study Sites (1)

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, 1011, Switzerland

Location

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• John O Prior, PhD MD

  Centre Hospitalier Universitaire Vaudois - Lausanne University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Nuclear Medicine Department, PhD MD

Study Record Dates

• First Submitted: June 11, 2022
• First Posted: June 15, 2022
• Study Start: February 8, 2023
• Primary Completion: April 9, 2024
• Study Completion: April 30, 2024
• Last Updated: June 18, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)